Rapid neuroadaptation in the nucleus accumbens and bed nucleus of the stria terminalis mediates suppression of operant responding during withdrawal from acute opioid dependence.
Single injections of morphine induce a state of acute opioid dependence in humans and animals, measured as precipitated withdrawal when an antagonist is administered 4-24 h after morphine. Additional morphine exposure at daily or weekly intervals results in further increases in withdrawal severity, suggesting that acute opioid dependence reflects the early stages in the development of a chronic state of dependence. The current study evaluated the role of the nucleus accumbens (NAC), bed nucleus of stria terminalis (BNST), interstitial nucleus of posterior limb of the anterior commissure (IPAC), and central amygdala (CeA) in the expression of antagonist-precipitated suppression of operant responding for food as a measure of withdrawal from acute opioid dependence. Rats trained on a fixed-ratio 15 schedule received one or four daily injections of morphine, with the lipophobic opioid antagonist methylnaloxonium (16-2000 ng) infused into one of the brain regions or the lateral ventricle (i.c.v.) 4 h after the final morphine injection. After acute morphine methylnaloxonium was more potent upon infusion into the NAC (17.9-fold potency shift), BNST (6.8-fold) and CeA (5.5-fold) than it was upon i.c.v. administration. Following repeat morphine the NAC and BNST but not CeA continued to show greater sensitivity relative to i.c.v. infusion (12.9-, 8.7-, and 3.2-fold potency shifts, respectively). The IPAC was insensitive to methylnaloxonium after acute or repeat morphine at doses that reliably suppressed responding upon i.c.v. infusion (125-500 ng). Thus, among the components of extended amygdala examined in this study, rapid neuroadaptation within the nucleus accumbens and bed nucleus of the stria terminalis appear to play the most prominent role in antagonist-precipitated suppression of operant responding during the early stages in the development of opioid dependence.
Criner
S H
SH
Department of Biology, University of California, San Diego, 9500 Gilman Drive, LA Jolla, CA 92093, USA.
Liu
J
J
Schulteis
G
G
D000222:Adaptation, Physiological / Q000187:drug effects / Q000502:physiology*; D000679:Amygdala / Q000187:drug effects / Q000503:physiopathology; D000818:Animals; D003216:Conditioning, Operant / Q000502:physiology*; D008297:Male; D009020:Morphine / Q000009:adverse effects; D009270:Naloxone / Q000009:adverse effects / Q000031:analogs & derivatives; D009292:Narcotic Antagonists / Q000009:adverse effects; D009294:Narcotics / Q000009:adverse effects; D009714:Nucleus Accumbens / Q000187:drug effects / Q000503:physiopathology*; D009293:Opioid-Related Disorders / Q000503:physiopathology*; D000644:Quaternary Ammonium Compounds / Q000009:adverse effects; D051381:Rats; D017208:Rats, Wistar; D012686:Septal Nuclei / Q000187:drug effects / Q000503:physiopathology*; D013375:Substance Withdrawal Syndrome / Q000503:physiopathology*
D009292:Narcotic Antagonists; D009294:Narcotics; D000644:Quaternary Ammonium Compounds; D009270:Naloxone; C041269:N-methylnaloxone; D009020:Morphine